Scholar Rock Q2 net loss $0.60/shr; cash $190.5M; Phase 3 SAPPHIRE data on track Q4 2024

Scholar Rock Holding Corp

2024-Q2 EPS reported -$1.20

Net loss $58.5M ($0.60/shr) vs $37.9M ($0.47/shr) in Q2 2023; no revenue.
Cash $190.5M; expected to fund operations into H2 2025.
Phase 3 SAPPHIRE topline data for apitegromab in SMA expected Q4 2024; commercial launch targeted 2025 if successful.
Phase 2 EMBRAZE (apitegromab + GLP-1 in obesity) now expects topline data Q2 2025; IND for SRK-439 planned in 2025.
Long-term TOPAZ data: 48-month mean HFMSE improvement 5.3 points (2-21 yrs); >90% patient retention.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.